ArticleAntibiotics (Basel, Switzerland)2020
Narrow-Spectrum Antibacterial Agents-Benefits and Challenges.
Article in Antibiotics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Optimizing intravenous amoxicillin for outpatient parenteral antimicrobial therapy.JAC-antimicrobial resistance · 2026Article
- A DPP inhibitor suppresses periodontitis via antibacterial effect targeting Porphyromonas gingivalis.Scientific reports · 2026Article
- Mode of action guided metagenomic natural product discovery reveals convergent evolution of a ClpP-targeting motif.Nature communications · 2026Article
- Multi task learning based early prediction model for antibiotic resistance using multi institutional cohort data.Scientific reports · 2026Article
- Impact of a Pharmacist-Driven Penicillin Allergy De-Labeling Service (PADLS) on Hospitalized Patients.Pharmacy (Basel, Switzerland) · 2026Article
- The functions of gut microbiota-mediated bile acid metabolism in intestinal immunity.Journal of advanced research · 2026Review
- Antimicrobial stewardship from a One Health perspective.Nature reviews. Microbiology · 2026Review
- Article
- Biogenic Selenium Nanoparticles fromPharmaceutics · 2025Article
- Exploring the antibacterial potential of environmental Pseudomonas aeruginosa isolates: Insights from in vitro studies and genome mining approaches.Journal, genetic engineering & biotechnology · 2025Article
- Novel Crown Ether-Functionalized Fusidic Acid Butyl Ester: Synthesis, Biological Evaluation, In Silico ADMET, and Molecular Docking Studies.Molecules (Basel, Switzerland) · 2025Article
- Fabrication of disposable microextraction analytical tool forRSC advances · 2025Article
- A multi-strategy antimicrobial discovery approach reveals new ways to treat Chlamydia.PLoS biology · 2025Article
- Microbiome Integrity Enhances the Efficacy and Safety of Anticancer Drug.Biomedicines · 2025Review
- Veterinarians' perspectives on livestock diseases and antimicrobial use in Palestine.Veterinary world · 2025Article
- Optical tuning of polymer functionalized zinc oxide quantum dots as a selective probe for the detection of antibiotics.Scientific reports · 2025Article
- A global investigation into antimicrobial knowledge in medicine, pharmacy, nursing, dentistry and veterinary undergraduate students: A scoping review to inform future planetary health multidisciplinary education.BMC medical education · 2024Article
- Novel Drug-like HsrA Inhibitors Exhibit Potent Narrow-Spectrum Antimicrobial Activities againstInternational journal of molecular sciences · 2024Article
- Management of Clostridioides difficile infection: an Italian Delphi consensus.The Journal of antimicrobial chemotherapy · 2024Article
- Systematic analysis of microorganisms' metabolism for selective targeting.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The number of antibacterial agents in clinical and preclinical development possessing activity against a narrow spectrum of bacterial pathogens is increasing, with many of them being nontraditional products. The key value proposition hinges on sparing antibiotic use and curtailing the emergence of resistance, as well as preventing the destruction of a beneficial microbiome, versus the immediate need for effective treatment of an active infection with a high risk of mortality. The clinical use of a targeted spectrum agent, most likely in combination with a rapid and robust diagnostic test, is a commendable goal with significant healthcare benefits if executed correctly. However, the path to achieving this will come with several challenges, and many scientific and clinical development disciplines will need to align their efforts to successfully change the treatment paradigm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.